Equities
  • Price (SEK)6.37
  • Today's Change-0.11 / -1.70%
  • Shares traded565.19k
  • 1 Year change-49.44%
  • Beta0.8747
Data delayed at least 15 minutes, as of Feb 09 2026 17:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

OssDsign AB, formerly known as Oss-Q AB is a Sweden-based orthopedic medical device company. It aims at developing implantable products that respond to clinical challenges, with focus on bone healing. Its primary focus is skull surgery. The Company uses design solutions, material compositions and manufacturing processes mainly based on proprietary bioceramic technologies. The bioceramics it uses integrate with tissues and support bone ingrowth. OssDsign AB's main product is Craniomosaic, an implant for the repair of skull defects (cranioplasty). Along with it, the Company develops bioceramic implants for facial bone augmentation. The Company's customers include neurosurgeons, craniofacial and maxillofacial surgeons.

  • Revenue in SEK (TTM)180.16m
  • Net income in SEK-50.99m
  • Incorporated2011
  • Employees32.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ortoma AB77.19m-7.52m469.31m10.00--2.9889.886.08-0.2027-0.20272.084.450.42433.9539.137,530,537.00-4.13-9.37-4.45-10.4341.26158.24-9.74-78.903.02--0.00--28.77--46.83---0.5751--
Q linea AB8.40m-188.37m485.10m83.00--2.02--57.78-93.10-93.102.1212.690.05710.54094.3789,308.51-128.17-71.92-306.62-84.15-110.15-303.58-2,243.85-3,994.181.28-62.880.3537---46.8018.645.45---49.88--
Bactiguard Holding AB228.77m-7.84m509.12m153.00--1.8212.972.23-0.2238-0.22386.538.990.3813.446.911,495,216.00-1.31-8.02-1.86-10.1363.7848.56-3.43-25.101.38-0.33870.3410---12.644.2273.69---17.92--
Modulight Oyj72.12m-49.18m527.12m71.00--1.09--7.31-0.1172-0.11720.17271.070.1254-0.79434.78102,484.90-8.55-9.90-9.25-10.66129.94119.43-68.15-88.503.46--0.081--1.74-10.6545.65--24.38--
Nanexa AB10.58m-39.06m592.66m15.00--7.66--56.04-0.2644-0.26440.06940.48740.097224.671.54813,538.40-35.91-37.21-42.59-44.9569.5693.79-369.29-355.052.07-21.980.2165---16.9370.1167.40--21.42--
BioPorto A/S52.18m-123.88m671.30m48.00--12.28--12.86-0.1973-0.19730.0830.07740.41322.554.69962,131.60-98.08-65.22-133.92-88.7463.9064.15-237.40-222.221.71--0.1916--17.076.36-21.15---20.56--
OssDsign AB180.16m-50.99m716.86m32.00--2.31--3.98-0.5493-0.54932.062.800.51090.36726.955,629,938.00-14.46-25.42-16.05-28.5996.2985.57-28.30-82.426.33-13.770.0044--34.5148.59-2.68--24.28--
Senzime AB (publ)89.71m-120.62m736.55m50.00--2.11--8.21-0.8672-0.86720.63942.220.2341.735.991,794,120.00-31.47-35.09-34.04-37.5241.868.75-134.46-400.654.30-7.700.0399--63.5554.1811.50--40.12--
Omda AS442.21m-28.19m803.93m260.00--25.3629.131.82-1.51-1.5123.591.630.679326.5921.701,772,075.00-4.33-5.14-5.39-6.6393.6991.09-6.37-10.320.64830.52810.9359--3.4515.80-163.95---15.57--
Gentian Diagnostics ASA160.64m39.83m830.02m63.0021.144.4117.215.172.732.7311.0713.100.81811.637.832,738,365.0020.29-2.9922.99-3.3655.0644.6624.80-5.844.16--0.0094--12.5225.96525.37--22.08--
Optomed Oyj185.34m-61.26m885.26m112.00--3.76--4.78-0.2915-0.29150.88031.030.58472.405.47151,147.80-19.33-14.59-23.47-17.4164.6465.60-33.05-31.361.60-20.890.1221---0.39740.084-22.72--8.10--
Nexstim Oyj107.32m-3.02m976.81m40.00--28.69138.029.10-0.042-0.0421.470.44260.85530.56134.66251,616.80-2.40-12.40-4.17-20.7694.3695.09-2.81-16.291.080.78350.6002--20.5521.1432.79--15.13--
Sedana Medical AB (publ)197.61m-40.65m987.41m117.00--1.09--5.00-0.4092-0.40921.999.140.20121.469.472,670,406.00-4.14-4.90-4.34-5.1670.4768.32-20.57-30.263.28-21.900.0045--16.1720.0682.09--26.45--
C Rad AB457.70m23.25m1.04bn107.0045.653.0030.612.270.69220.692213.5810.53------4,623,273.00--8.44--11.7351.4545.005.088.282.983.310.02520.0010.4517.9658.88---9.15--
ADDvise Group AB (publ)1.62bn4.30m1.04bn615.0019.910.94029.370.64160.08640.08643.441.830.51677.914.962,534,790.000.13993.410.1744.2839.9146.520.27086.060.75621.620.52510.438921.6836.71-13.0485.8552.63--
Data as of Feb 09 2026. Currency figures normalised to OssDsign AB's reporting currency: Swedish Krona SEK

Institutional shareholders

11.03%Per cent of shares held by top holders
HolderShares% Held
East Capital Financial Services ABas of 10 Jul 20243.09m2.80%
Wahlstedt & Partners ABas of 31 Dec 20252.71m2.45%
Amundi Asset Management SASU (Investment Management)as of 31 Dec 20252.41m2.18%
Financi�re de l'�chiquier SAas of 31 Dec 20251.96m1.77%
Mandarine Gestion SAas of 30 Jun 20251.03m0.93%
Schroder Investment Management (Europe) SA (Finland)as of 30 Jun 20251.00m0.90%
More ▼
Data from 30 Sep 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.